This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magee, P. G. Articles by Gott, V. L. Search for Related Content PubMed PubMed Citation Articles by Magee, P. G. Articles by Gott, V. L.

Circulation, Vol 60, 151-157, Copyright © 1979 by American Heart Association

ARTICLES

Comparison of myocardial protection with nifedipine and potassium

PG Magee, JT Flaherty, TJ Bixler, D Glower, TJ Gardner, BH Bukley and VL Gott

Nifedipine, a slow-channel calcium blocker, is thought to provide useful myocardial protection during prolonged total ischemia and reperfusion. An isolated, isovolumic, feline heart model was used to asses the effectiveness of nifedipine in both cardioplegic (100 microgram/10 ml) and noncardioplegic (10 microgram/10 ml) doses for providing myocardial preservation during 90 minutes of hypothermic ischemic arrest and 45 minutes of normothermic reperfusion. Use of nifedipine was compared to hypothermia (27 degrees C) alone and to hypothermia with potassium cardioplegia. Ventricular function was assessed by recovery of isovolumic left ventricular developed pressure and dP/dt. Myocardial carbon dioxide tension (PCO2) and myocardial oxygen tension (PO2) were measured by mass spectrometry. Potassium cardioplegia and the higher dose of nifedipine resulted in immediate asystole. The rates of rise of PCO were greatest in the group receiving 10 microgram nifedipine and in the control group. The rates of rise in the two cardioplegic groups were significantly lower. Recovery of ventricular function was significantly lower with low-dose nifedipine than with potassium cardioplegia. Higher dose nifedipine resulted in a return of function, which was no different than with potassium cardioplegia. Morphologic protection was better with higher dose nifedipine and potassium cardioplegia than with either low-dose cardioplegia or hypothermia alone. These results demonstrate that nifedipine in a cardioplegic dose results in preservation of myocardial structure and function that is similar to that obtained with potassium cardioplegia. In lower noncardioplegic dose, nifedipine does not appear to offer additional protection compared to hypothermia alone. Whether persistent depression of ventricular contractility will limit nifedipine's clinical usefulness as a myocardial protection agent will require further study.

This article has been cited by other articles:

				G. Noera, C. Massini, and G. Baggio In vitro plasma nifedipine concentration during heart-lung machine function Perfusion, October 1, 1987; 2(4): 277 - 281. [Abstract] [PDF]

				M. D. Winniford, J. T. Willerson, and L. D. Hillis Calcium Antagonists in the Treatment of Individuals with Ischemic Heart Disease Angiology, August 1, 1982; 33(8): 522 - 539. [Abstract] [PDF]

				P. H. STONE, E. M. ANTMAN, J. E. MULLER, and E. BRAUNWALD Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part II: Hemodynamic Effects and Clinical Applications Ann Intern Med, December 1, 1980; 93(6): 886 - 904. [Abstract] [PDF]